Antibacterial agent 357

Antibacterial agent 357 (Compound 7d) (18 h) potently inhibits the growth of Staphylococcus aureus ATCC 29213, Enterococcus faecalis ATCC 29212, Escherichia coli ATCC 25922, Stenotrophomonas maltophilia ATCC 17808, MRSA isolates and Gram-negative isolates, with MIC values ranging from 0.5 to 4 μg/mL. Meanwhile, this agent exhibits low hemolytic toxicity (HC₅₀ > 320 μg/mL) and a selectivity index > 640^[1].
Antibacterial agent 357 (1-16 μg/mL) dose-dependently inhibits biofilm formation of S. aureus ATCC 29213 and disrupts pre-formed mature biofilms; at a concentration of 16 μg/mL, it reduces the survival rate of bacteria within the biofilm to <0.04%^[1].
Antibacterial agent 357 (0.125-16 μg/mL; 10 mM NAC) exerts bactericidal activity against Staphylococcus aureus ATCC 29213 by disrupting bacterial cell membranes (targeting phosphatidylglycerol), inducing ROS accumulation, and causing morphological damage^[1].
Antibacterial agent 357 alters the gene expression of S. aureus ATCC 29213, upregulating stress response pathways associated with membrane modification while downregulating pathways involved in protein synthesis and energy metabolism, which confirms its mechanism of action involving membrane disruption, ROS accumulation and metabolic disorder^[1].
Antibacterial agent 357 (0.5-8 μg/mL; 24 h) exhibits favorable in vitro safety against GES cells, with a CC₅₀ of 18.3 μg/mL. The cell survival rate exceeds 80% at the concentration of 8 μg/mL, and no significant membrane damage is observed^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.